Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Zejula
Zejula
ESMO 2019 preview – PARPs on parade
EP Vantage
Thu, 09/5/19 - 12:06 pm
ESMO
PARP inhibitors
Lynparza
AstraZeneca
ovarian cancer
GSK
Zejula
GSK drug helps ovarian cancer patients live longer in late-stage study
Yahoo/Reuters
Mon, 07/15/19 - 09:59 am
GSK
Zejula
ovarian cancer
clinical trials
GSK wins speedy FDA Zejula review in ovarian cancer niche
Fierce Pharma
Mon, 06/24/19 - 07:13 pm
GSK
FDA
Zejula
ovarian cancer
late-stage ovarian cancer
Tesaro
Anatomy of a long-delayed biotech buyout: With its stock price beaten down, abandoned by potential bidders, Tesaro wound up in GSK’s eager arms
Endpoints
Sat, 12/15/18 - 11:44 pm
M&A
Tesaro
Zejula
GSK
GSK Pays $5.1B For Tesaro, Setting Up “PARP” Battle With Rival AstraZeneca
Xconomy
Mon, 12/3/18 - 10:11 am
GSK
M&A
Tesaro
PARP inhibitors
Zejula
AstraZeneca
PARPs may be crushing it in the clinic, but half of doctors are still wary: executive
Fierce Pharma
Wed, 10/24/18 - 12:38 pm
PARP inhibitors
physicians
Zejula
Rubraca
Lynparza
AstraZeneca
Merck
Tesaro
Clovis Oncology
PARP inhibitors show promise for treating ALS and other brain disorders
Fierce Biotech
Thu, 08/9/18 - 10:04 pm
PARP inhibitors
AstraZeneca
Lynparza
Tesaro
Zejula
ALS
Tesaro CEO Says Its Drug 'Will Get There' — Analysts Strongly Disagree
Investors.com
Sat, 08/4/18 - 11:51 am
Tesaro
Zejula
ovarian cancer
Tesaro Wants a Stronger Grip in Ovarian Cancer
Yahoo/Motley Fool
Tue, 03/27/18 - 10:10 pm
Tesaro
AstraZeneca
Clovis Oncology
ovarian cancer
Zejula
Rubraca
Lynparza
Preliminary positive results for Phase I - II trial of Tesaro's Zejula with Keytruda in platinum-resistant ovarian cancer (TSRO)
CP Wire
Mon, 03/26/18 - 02:48 pm
Tesaro
Zejula
Merck
Keytruda
platinum-resistant ovarian cancer
niraparib
clinical trials vaccines
Preliminary positive results for Phase I - II trial of Tesaro's Zejula with Keytruda in platinum-resistant ovarian cancer
Mon, 03/26/18 - 02:41 pm
Tesaro
Zejula
Merck
Keytruda
platinum-resistant ovarian cancer
niraparib
clinical trials
AstraZeneca Goes Up Against 2 Cancer Upstarts
Motley Fool
Sat, 03/10/18 - 09:17 am
AstraZeneca
Clovis Oncology
PARP inhibitors
Lynparza
ovarian cancer
breast cancer
Rubraca
Zejula
In wake of Tecentriq bladder cancer bust and lost market share, Roche tries Tesaro combo
Fierce Pharma
Tue, 02/27/18 - 06:45 pm
Roche
Tecentriq
bladder cancer
Zejula
PARP inhibitors
3 Companies Competing to Gain Lead in Ovarian Cancer Market
Yahoo/Zacks.com
Sat, 11/25/17 - 12:35 pm
ovarian cancer
AstraZeneca
Merck
Lynparza
Rubraca
Clovis Oncology
Zejula
Tesaro
AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth
Fierce Pharma
Wed, 11/15/17 - 08:51 pm
AstraZeneca
Merck
Clovis Oncology
Tesaro
PARP inhibitors
ovarian cancer
Zejula
Rubraca
Lynparza
AstraZeneca, Tesaro and Clovis need to slash the cost of PARP meds, watchdog says
Fierce Pharma
Mon, 10/2/17 - 10:10 pm
AstraZeneca
Tesaro
Clovis Oncology
PARP inhibitors
drug pricing
ovarian cancer
Lynparza
Zejula
Rubraca
Watch out Tesaro, AstraZeneca and Merck get FDA OK for broad use of Lynparza
Endpoints
Thu, 08/17/17 - 11:54 pm
Tesaro
AstraZeneca
Merck
FDA
Lynparza
Zejula
Tesaro's Zejula rolls to No. 1 PARP position with big Q2
Fierce Pharma
Wed, 08/16/17 - 10:05 am
Tesaro
Zejula
PARP inhibitors
earnings
Tesaro partners with Takeda in Asia, bagging a $340M deal for Zejula
Endpoints
Thu, 07/27/17 - 09:52 am
Tesaro
Takeda
Japan
Zejula
Pages
« first
‹ previous
1
2